Sultan Sadia, Irfan Syed Mohammed
Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College, Karachi, Pakistan E-mail :
Asian Pac J Cancer Prev. 2015;16(17):7889-92. doi: 10.7314/apjcp.2015.16.17.7889.
Primary idiopathic myelofibrosis (PMF) is a clonal Ph-chromosome negative myeloproliferative neoplasm characterized by dysregulated kinase signaling and release of abnormal cytokines. In the recent past, following JAK2 V617F mutation invention, important revolution has been made in the molecular diagnostic biology of this disease. The rational of this study was to determine the mutational status of JAK2 V617F in Pakistan patients with PMF.
In this cross sectional study, 20 patients with PMF were enrolled from January 2011 to December 2014. Diagnosis was based on WHO criteria for PMF. All patients were screened for G-T point mutation (V617F) in the JAK2 gene on chromosome 9 by allele specific PCR.
The mean age was 57.9 ± 16.5 years. The male to female ratio was 3:1. The frequency of JAK2 V617F positivity in our PMF patients was found to be 55%. Positive correlations of JAK2 V617F mutation were established with high TLC count, raised LDH and marked splenomegaly (P<0.05). No correlation of JAK2 V617F could be established with age and gender (P>0.05).
The JAK2 V617F mutation frequency in our PMF patients was similar to those reported previously. In our hands JAK2 V617F mutated patients expressed an aggressive disease phenotype. Screening for the mutation in all suspected PMF cases could be beneficial in differentiating patients with reactive and clonal marrow fibrosis.
原发性特发性骨髓纤维化(PMF)是一种克隆性Ph染色体阴性骨髓增殖性肿瘤,其特征为激酶信号失调和异常细胞因子释放。近期,随着JAK2 V617F突变的发现,该疾病的分子诊断生物学取得了重要进展。本研究的目的是确定巴基斯坦PMF患者中JAK2 V617F的突变状态。
在这项横断面研究中,2011年1月至2014年12月纳入了20例PMF患者。诊断依据WHO的PMF标准。所有患者通过等位基因特异性PCR筛查9号染色体上JAK2基因的G-T点突变(V617F)。
平均年龄为57.9±16.5岁。男女比例为3:1。我们的PMF患者中JAK2 V617F阳性频率为55%。JAK2 V617F突变与高白细胞计数、升高的乳酸脱氢酶和明显的脾肿大呈正相关(P<0.05)。JAK2 V617F与年龄和性别无相关性(P>0.05)。
我们的PMF患者中JAK2 V617F突变频率与先前报道的相似。在我们的研究中,JAK2 V617F突变患者表现出侵袭性疾病表型。对所有疑似PMF病例进行突变筛查可能有助于区分反应性和克隆性骨髓纤维化患者。